Providing solutions for today’s challenges and tomorrow’s imperatives

Drug discovery

Target identification

ProQomics enables the precise quantitation of proteoforms, helping researchers uncover new targets that are modulated in disease states. Our platform provides the detailed protein-level data needed to confidently pursue novel targets with therapeutic potential.

Assay development

The ProQomics platform supports assay development by providing high-resolution data on proteoform interactions and activities. Our technology allows for the development of robust, reproducible assays that can accurately measure the effects of potential therapeutics on target proteoforms, ensuring that assays are both sensitive and specific.

Lead selection

ProQomics’ high-throughput quantitation of proteoforms enables researchers to evaluate the efficacy and specificity of multiple leads rapidly. By providing detailed insights into how each compound affects proteoform expression and function, our platform aids in the selection of the most promising therapeutic candidates.

Biomarkers

ProQomics supports the discovery and validation of proteoform-based biomarkers that can be used throughout the drug development process. Our platform provides the sensitivity and precision needed to identify and quantify biomarkers that reflect drug activity and patient response.

IND filing

ProQomics’ technology provides the proteomic insights needed to support IND submissions, including detailed analyses of target engagement, biomarker validation, and toxicology. Our platform ensures that your IND filing is backed by robust, high-quality data.

Trial design

ProQomics’ platform aids in trial design by providing insights into proteoform dynamics, helping to define patient stratification criteria, identify relevant biomarkers, and optimize dosing strategies. Our technology ensures that clinical trials are informed by the most accurate and comprehensive proteomic data available.

Toxicology

ProQomics’ platform enables detailed toxicological studies by quantifying proteoforms that are indicative of drug-induced toxicity. Our technology provides the sensitivity and precision needed to detect early signs of toxicity, helping to ensure the safety of drug candidates before they advance to clinical trials.

Drug repurposing

ProQomics’ platform supports drug repurposing efforts by revealing new proteoform targets that are modulated by existing drugs. Our high-throughput technology enables researchers to quickly identify potential new uses for approved drugs, offering a faster path to market for repurposed therapeutics.